Program
VH4524184
A development code. Also written as “VH4524184 Formulation A IM” and “VH4524184 Formulation B IM”.
In GlaxoSmithKline's pipeline, HIV integrase inhibitor
. Its studies are mostly in HIV Infections, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 73 open or running | phase 2since Jan 9, 2024 | Nov 18, 2022 | Oct 28, 2027phase 2 · NCT07202546 |
- Named in GlaxoSmithKline’s own pipeline as
VH4524184
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 18, 2022First study: phase 1 study in HIV InfectionsFirst studyNCT05631704 · 84 enrolled · United States
- Jan 9, 2024Phase 2 study in HIV InfectionsNCT06214052 · 22 enrolled · United States, Argentina, Canada and more
- Mar 1, 20242 phase 1 studies in HIV InfectionsNCT06310616, NCT06310551
- Jul 3, 2025Phase 1 study in HIV InfectionsNCT07066722 · 126 enrolled · United States
- Sep 30, 2025Phase 2 study in HIV InfectionsNCT07202546 · 186 planned · United States, Argentina, Australia and more
- May 29, 2026Phase 1 study in HIV InfectionsNCT07636928 · 9 planned · Netherlands
- Nov 5, 2026Primary completion moved from 2028-01-21 to 2029-05-28Date moved laterphase 1 · +16 months · NCT06310551
- Nov 12, 2026Primary completion moved from 2027-06-11 to 2027-10-28Date moved laterphase 2 · +5 months · NCT07202546
Ahead
- Oct 28, 2027Primary completion: phase 2 study in HIV InfectionsNCT07202546
- May 28, 2029Primary completion: phase 1 study in HIV InfectionsNCT06310551
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“HIV integrase inhibitor”the company's pipeline, read by Claude · source
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07636928HIV Infections · Netherlands | 1 | Recruiting | Aug 20, 2026 | 9 |
| NCT07202546HIV Infections · United States, Argentina, Australia and more | 2 | Recruiting | Oct 28, 2027 | 186 |
| NCT07066722HIV Infections · United States | 1 | Completed | Dec 17, 2025 | 126 |
| NCT06310551HIV Infections · United States | 1 | Recruiting | May 28, 2029 | 348 |
| NCT06310616HIV Infections · United States | 1 | Completed | Aug 15, 2024 | 26 |
| NCT06214052HIV Infections · United States, Argentina, Canada and more | 2 | Completed | Jun 12, 2024 | 22 |
| NCT05631704HIV Infections · United States | 1 | Completed | Jul 27, 2023 | 84 |
How it is read
Names in the registry
- “VH4524184”, 6 entries
- “VH4524184 Formulation A IM”, 1 entry
- “VH4524184 Formulation B IM”, 1 entry
Codes read as this program: VH4524184.
Conditions, from the studies’ own filings
- HIV Infections, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.